Bemiparin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Bemiparin
Accession Number
DB09258
Type
Small Molecule
Groups
Approved, Investigational
Description

Bemiparin is an antithrombotic and belongs to the group of low molecular weight heparins (LMWH). Like semuloparin, bemiparin is classified as an ultra-LMWH because of its low molecular mass of 3600 Daltons on average. These heparins have lower anti-thrombin activity than classical LMWHs and act mainly on factor Xa, reducing the risk of bleeding.

Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Bemiparin sodiumP59JKU02CENot AvailableNot applicable
Categories
UNII
PUE0TO3XDR
CAS number
91449-79-5
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Used in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabBemiparin may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolBemiparin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Bemiparin.Approved, Vet Approved
AliskirenBemiparin may increase the hyperkalemic activities of Aliskiren.Approved, Investigational
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Bemiparin.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Bemiparin.Approved, Investigational
AmilorideBemiparin may increase the hyperkalemic activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Bemiparin.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Bemiparin.Approved
AncrodBemiparin may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Bemiparin.Investigational
Antithrombin III humanBemiparin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanBemiparin may increase the anticoagulant activities of Apixaban.Approved
AprotininThe therapeutic efficacy of Bemiparin can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArdeparinBemiparin may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanBemiparin may increase the anticoagulant activities of Argatroban.Approved, Investigational
AzelastineAzelastine may increase the anticoagulant activities of Bemiparin.Approved
Azilsartan medoxomilBemiparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved, Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Bemiparin.Approved, Investigational
BecaplerminBemiparin may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeraprostBeraprost may increase the anticoagulant activities of Bemiparin.Investigational
BivalirudinBemiparin may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BuflomedilBuflomedil may increase the anticoagulant activities of Bemiparin.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Bemiparin.Investigational
CanagliflozinBemiparin may increase the hyperkalemic activities of Canagliflozin.Approved
CandesartanBemiparin may increase the hyperkalemic activities of Candesartan.Experimental
Candesartan cilexetilBemiparin may increase the hyperkalemic activities of Candesartan cilexetil.Approved
CangrelorCangrelor may increase the anticoagulant activities of Bemiparin.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Bemiparin.Experimental, Investigational
CertoparinBemiparin may increase the anticoagulant activities of Certoparin.Approved, Investigational
CilostazolCilostazol may increase the anticoagulant activities of Bemiparin.Approved, Investigational
Citric AcidBemiparin may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Bemiparin.Approved
CloricromenCloricromen may increase the anticoagulant activities of Bemiparin.Experimental
Dabigatran etexilateBemiparin may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinBemiparin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidBemiparin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanBemiparin may increase the anticoagulant activities of Darexaban.Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Bemiparin.Approved, Investigational
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Bemiparin.Investigational
DesirudinBemiparin may increase the anticoagulant activities of Desirudin.Approved
DextranBemiparin may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Dextran 40Bemiparin may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Bemiparin may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Bemiparin may increase the anticoagulant activities of Dextran 75.Approved
DicoumarolBemiparin may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Bemiparin.Approved, Investigational
DipyridamoleDipyridamole may increase the anticoagulant activities of Bemiparin.Approved
Edetic AcidBemiparin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanBemiparin may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinBemiparin may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Bemiparin.Approved, Investigational
EplerenoneBemiparin may increase the hyperkalemic activities of Eplerenone.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Bemiparin.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Bemiparin.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Bemiparin.Approved
EprosartanBemiparin may increase the hyperkalemic activities of Eprosartan.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Bemiparin.Approved, Investigational
Ethyl biscoumacetateBemiparin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ferulic acidBemiparin may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanBemiparin may increase the hyperkalemic activities of Fimasartan.Approved, Investigational
FluindioneBemiparin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FondaparinuxBemiparin may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumBemiparin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanBemiparin may increase the hyperkalemic activities of Forasartan.Experimental
GabexateBemiparin may increase the anticoagulant activities of Gabexate.Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Bemiparin.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Bemiparin.Experimental
HeparinBemiparin may increase the anticoagulant activities of Heparin.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Bemiparin.Investigational
IbudilastIbudilast may increase the anticoagulant activities of Bemiparin.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Bemiparin.Approved, Investigational, Nutraceutical
IdraparinuxBemiparin may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Bemiparin.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Bemiparin.Investigational
IloprostIloprost may increase the anticoagulant activities of Bemiparin.Approved, Investigational
IndobufenIndobufen may increase the anticoagulant activities of Bemiparin.Investigational
IrbesartanBemiparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
KetanserinKetanserin may increase the anticoagulant activities of Bemiparin.Investigational
LepirudinBemiparin may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanBemiparin may increase the anticoagulant activities of Letaxaban.Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Bemiparin.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Bemiparin.Experimental
LosartanBemiparin may increase the hyperkalemic activities of Losartan.Approved
MelagatranBemiparin may increase the anticoagulant activities of Melagatran.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Bemiparin.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Bemiparin.Approved, Vet Approved
MilrinoneMilrinone may increase the anticoagulant activities of Bemiparin.Approved
NadroparinBemiparin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatBemiparin may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilNaftopidil may increase the anticoagulant activities of Bemiparin.Investigational
NimesulideNimesulide may increase the anticoagulant activities of Bemiparin.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Bemiparin.Investigational
OlmesartanBemiparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Bemiparin.Approved
OtamixabanBemiparin may increase the anticoagulant activities of Otamixaban.Investigational
PaliferminThe serum concentration of Palifermin can be increased when it is combined with Bemiparin.Approved
Pentaerythritol TetranitrateBemiparin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateBemiparin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Bemiparin.Approved, Investigational
PhenindioneBemiparin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonBemiparin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PicotamidePicotamide may increase the anticoagulant activities of Bemiparin.Experimental
PrasugrelPrasugrel may increase the anticoagulant activities of Bemiparin.Approved
Protein CBemiparin may increase the anticoagulant activities of Protein C.Approved
Protein S humanBemiparin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeBemiparin may increase the anticoagulant activities of Protocatechualdehyde.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Bemiparin.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Bemiparin.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Bemiparin.Approved, Experimental, Investigational
ReviparinBemiparin may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Bemiparin.Approved
RivaroxabanBemiparin may increase the anticoagulant activities of Rivaroxaban.Approved
SacubitrilBemiparin may increase the hyperkalemic activities of Sacubitril.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Bemiparin.Approved, Investigational, Vet Approved
SaprisartanBemiparin may increase the hyperkalemic activities of Saprisartan.Experimental
SaralasinBemiparin may increase the hyperkalemic activities of Saralasin.Investigational
SarpogrelateSarpogrelate may increase the anticoagulant activities of Bemiparin.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Bemiparin.Approved, Vet Approved
SpironolactoneBemiparin may increase the hyperkalemic activities of Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Bemiparin.Investigational
SulodexideBemiparin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TasosartanBemiparin may increase the hyperkalemic activities of Tasosartan.Approved
TelmisartanBemiparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
TesmilifeneTesmilifene may increase the anticoagulant activities of Bemiparin.Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Bemiparin.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Bemiparin.Approved
TirofibanTirofiban may increase the anticoagulant activities of Bemiparin.Approved
TranilastTranilast may increase the anticoagulant activities of Bemiparin.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Bemiparin.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Bemiparin is combined with Treprostinil.Approved, Investigational
TriamtereneBemiparin may increase the hyperkalemic activities of Triamterene.Approved
TriflusalTriflusal may increase the anticoagulant activities of Bemiparin.Approved, Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Bemiparin.Approved
TroxerutinBemiparin may increase the anticoagulant activities of Troxerutin.Investigational
ValsartanBemiparin may increase the hyperkalemic activities of Valsartan.Approved, Investigational
VorapaxarVorapaxar may increase the anticoagulant activities of Bemiparin.Approved
WarfarinBemiparin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranBemiparin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
  1. Chapman TM, Goa KL: Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis. Drugs. 2003;63(21):2357-77. [PubMed:14524738]
  2. Planes A: Review of bemiparin sodium--a new second-generation low molecular weight heparin and its applications in venous thromboembolism. Expert Opin Pharmacother. 2003 Sep;4(9):1551-61. [PubMed:12943485]
  3. Jeske WP, Hoppensteadt D, Gray A, Walenga JM, Cunanan J, Myers L, Fareed J, Bayol A, Rigal H, Viskov C: A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin. Thromb Res. 2011 Oct;128(4):361-7. doi: 10.1016/j.thromres.2011.03.001. Epub 2011 Apr 2. [PubMed:21458847]
External Links
PubChem Substance
347910422
Wikipedia
Bemiparin_sodium
ATC Codes
B01AB12 — Bemiparin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentImpaired Renal Function1
2CompletedTreatmentPeritoneal Diseases1
2TerminatedTreatmentCarcinoma, Small Cell1
2, 3TerminatedTreatmentDiabetic Angiopathies / Foot Ulcer, Diabetic1
3Active Not RecruitingPreventionCirrhosis and Coagulation1
3CompletedPreventionCancers / Venous Thromboembolism1
3CompletedTreatmentDeep Vein Thrombosis (DVT)1
3CompletedTreatmentFoot Ulcer, Diabetic1
3TerminatedPreventionCancers / Thrombosis1
3TerminatedTreatmentNeoplasms / Venous Thromboembolism1
4CompletedTreatmentAcute Gastrointestinal Bleeding1
4RecruitingTreatmentInfertilities1
Not AvailableCompletedPreventionDeep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)1
Not AvailableCompletedPreventionVenous Thromboembolic Diseases1
Not AvailableCompletedTreatmentVenous Thromboembolism1
Not AvailableRecruitingNot AvailableUnsuspected Pulmonary Embolism1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 26, 2015 10:50 / Updated on February 03, 2018 14:04